Thanks to the introduction of the drug Gleevec® and similar tyrosine kinase inhibitors, the number of patients with chronic myeloid leukemia (CML) who enter remission and stay in remission for years has increased dramatically over the past decade.
Relative Survival Rate
Relative survival compares (1) how long a person with a disease survives after being diagnosed to (2) how long a person without the disease lives. Survival statistics for CML are usually reported as five-year survival rates.
Adults' chance of remission has increased dramatically in the last 10 years because of the Food and Drug Administration's approval of Gleevec in 2001. The overall relative five-year survival rate for CML from 2003-2009 was 58.6 percent.
There will be an estimated 810 deaths from CML in 2014.
Treatment results and outcomes vary among patients. Newer treatment therapies like Gleevec, Sprycel and Tasigna, progress in stem cell transplantation, better supportive care and studies of new drugs in clinical trials are all contributing to improved outcomes and quality of life for people diagnosed with blood cancers.